Huake Run Completes Tens of Millions in Pre-C+ Round Funding, Accelerating the Development of a Comprehensive Ecosystem for Orthopedic Micro-Robots and Intelligent Digital Products

In recent years, Huake Run has achieved sustained, rapid growth in both product R&D and market sales. To date, the company has filed a total of 234 domestic patent applications, including 98 invention patents, 120 utility model patents, and 16 design patents, as well as 17 international patents (of which 8 have been granted). It has also obtained 20 Class II and 12 Class III NMPA medical device registration certificates, along with 13 CE certifications and 1 FDA 510(k) clearance. Its product portfolio spans vertebroplasty, spinal implants, sports medicine, orthopedic active devices and consumables, surgical robotics, and artificial intelligence, forming a “1+3+1” product strategy that leverages consumables and devices as dual growth drivers while fostering synergistic development between them. By delivering innovative products and superior quality, the company serves patients effectively and sustains robust year-over-year revenue growth.

In 2021, Huake Run invested over RMB 100 million in Interventional Systems (INS), a European innovative robotics company, and established a Sino-European joint venture in Shanghai—Sino-European Zhiwei (Shanghai) Robotics Co., Ltd.—marking a landmark milestone in the company’s expansion into the digital orthopedics and surgical robotics markets. The first-generation core product—the Intelligent Woodpecker Miniature Spinal Surgery Robot (a spinal surgery navigation and positioning system)—successfully passed the Special Review Application for Innovative Medical Devices submitted to the Medical Device Technical Review Center of the National Medical Products Administration in February 2024, becoming China’s first miniature orthopedic surgical robot to enter the innovative medical device green channel.

The Intelligent Woodpecker Miniature Spinal Surgery Robot is a next-generation, miniaturized intelligent surgical assistance system that boasts innovative features such as compact size, precision, efficiency, and intelligence. Equipped with a highly targeted surgical planning and navigation system, it enables full-process visualization and controllability of the procedure. The system comes with a comprehensive suite of surgical accessories, whose differentiated technological characteristics and user-friendly design address the practical needs of clinical users. The Intelligent Woodpecker system is fully compatible with all types of consumable products from Huake Run and is applicable across multiple fields, including spinal internal fixation surgery, spinal interventional procedures, and percutaneous endoscopic spinal surgery, thereby providing clinicians with a comprehensive, miniature, precision robotic-assisted surgical solution.

Centering on the Intelligent Woodpecker miniaturized spinal surgical robot, the company has further launched the [IDEAS³] Intelligent Digital Ecosystem of Advanced Spinal Surgical Solutions. Leveraging multi-modal fusion technology and preoperative and/or intraoperative planning, the [IDEAS³] ecosystem—supported by C-arm–guided real-time imaging, navigation-assisted guidance, and navigation-based positioning—integrates products from Huake Run and other authorized brands. It enables fully visualized manipulation of both active and passive surgical instruments throughout the entire procedure, empowering clinicians across a wide range of spinal surgical scenarios, including vertebroplasty, endoscopic decompression and fusion, and pedicle screw fixation for the entire spine. This approach delivers greater convenience, precision, intelligence, minimally invasive outcomes, and operational efficiency, thereby closing the loop between product systems and clinical needs.

Mr. Ma Yan, Chairman and General Manager of Huake Run Biotechnology Co., Ltd., stated: “The successful completion of this financing round has injected strong momentum into the company’s innovative R&D and market expansion across five core areas—orthopedic microsurgical robots, vertebroplasty, spinal internal fixation, sports medicine, and active medical devices. Our team will continue to refine and strengthen the construction of the ‘IDEAS³’ ecosystem. Looking ahead, we will leverage higher-quality innovative products and technical services to empower clinical practitioners and patient populations. At the same time, we look forward to welcoming more partners who embody diligence, resilience, and deep industry insight, so that together we can drive further progress in key areas such as product development, resource integration, team building, capacity upgrading, deepening our presence in the domestic market, and global expansion, ultimately co-building a robotics-driven, platform-based innovator in the field of minimally invasive orthopedics.”

Ms. Gu Guan, Partner at Chengshu Investment, stated: “Ningbo Huake Run is an exceptionally resilient and win-win–oriented innovator in the orthopedic devices sector. We have been closely following the company for many years, witnessing its journey from the successful commercialization of breakthrough, niche products to a strategic transformation into a robot-enabled, minimally invasive, innovation-driven orthopedic platform. We have also seen the company stand out in the first round of centralized procurement for spinal consumables and achieve rapid growth. We highly commend the core team’s unwavering strategic vision, relentless innovation capability, and exceptional execution. The company’s core product pipeline aligns with the trends toward minimally invasive and precision surgery, and under the long-term backdrop of population aging, it holds significant clinical value. It is a great honor to partner with Huake Run, and we look forward to seeing the company’s meticulously cultivated ‘Intelligent Digital Advanced Spine Ecosystem’ take deep root in China and expand globally.”

Chengshu Investment focuses on growth-stage and early-stage investments in the consumer healthcare, medical devices, and life sciences sectors. Its management team is a pioneer and builder in China’s capital markets and healthcare private equity, boasting extensive industry networks and deep capital-market expertise. They have a profound understanding of the dynamics of corporate growth and are committed to continuously empowering portfolio companies to achieve sustainable, long-term value creation for investors. “Focus, Growth, and Long-Term” is Chengshu’s guiding investment philosophy: identifying companies with substantial growth potential at the mid- and early stages and providing targeted capital and resource support during their critical inflection points; accompanying high-quality companies and entrepreneurs throughout their journey; and steadily increasing investments to co-create enduring, sustainable value over the long term.

- END -